Global Blood Therapeutics Inc.
GBT
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
15.9% upsideUndervalued by 15.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $397.23 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.82 |
| Beta | 0.46 |
| Outstanding Shares | 65,594,792 |
Return
| Return on Equity | -275.75% |
|---|---|
| Return on Assets | -37.50% |
| Return on Invested Capital | -38.26% |
Valuation & Multiples
| P/E Ratio | -14.21 |
|---|---|
| PEG | -76.79 |
| Price to Sales | 22.83 |
| Price to Book Ratio | 68.49 |
| Enterprise Value to Revenue | 1.69 |
| Enterprise Value to EBIT | -1.34 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.66 |
| Debt to Equity | 5.56 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Global Blood Therapeutics Inc.
CEO: Ted Love Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policy and corporate tax rates, which are the primary drivers of pharmaceutical profit margins.
Determines the specific funding for the FDA and NIH, directly impacting the speed of drug reviews and federal research support.
Directly regulates the FDA and NIH; members have access to non-public information regarding drug approvals and clinical trial guidelines.
Oversees intellectual property and patent law, which is the foundation of valuation for pharmaceutical companies and their drug exclusivity.